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Repetitive transcranial magnetic stimulation over the
orbitofrontal cortex for obsessive-compulsive disorder: a
double-blind, crossover study
C Nauczyciel1,2, F Le Jeune1,3,6, F Naudet1,2,4,6, S Douabin2, A Esquevin1,5, M Vérin1, T Dondaine1,2, G Robert1,2, D Drapier1,2 and
B Millet1,2
This pilot study was designed to assess the efﬁcacy of low-frequency repetitive transcranial magnetic stimulation (rTMS) over the
right orbitofrontal cortex (OFC) by means of a double-cone coil in patients suffering from obsessive-compulsive disorder. We
hypothesized that low-frequency stimulation of the OFC would lead to a reduction in clinical symptoms, as measured on the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS). A randomized, double-blind, crossover design was implemented with two 1-week
treatment periods (active stimulation versus sham stimulation) separated by a 1-month washout period. Concomitantly, a subgroup
of patients underwent a positron emission tomography (PET) scan after each stimulation sequence. Statistical analyses compared
the Y-BOCS scores at the end of each period. At day 7, we observed a signiﬁcant decrease from baseline in the Y-BOCS scores, after
both active (Po0.01) and sham stimulation (P= 0.02). This decrease tended to be larger after active stimulation than after sham
stimulation: − 6 (−29, 0) points versus − 2 (−20, 4) points (P= 0.07). Active versus sham PET scan contrasts showed that stimulation
was related to a bilateral decrease in the metabolism of the OFC. The OFC should deﬁnitely be regarded as a key neuroanatomical
target for rTMS, as it is easier to reach than either the striatum or the subthalamic nucleus, structures favored in neurosurgical
approaches.
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a frequent and chronic (1-
year prevalence: 1.5–2.1%) psychiatric disorder1 that is classically
treated with selective serotonin reuptake inhibitors (SSRIs) and
cognitive behavioral therapy (CBT).2 However, this combined
treatment is only efﬁcient in 20% patients, with partial remission
for 66%. The impairments in social and occupational functioning
caused by OCD fully justify the search for new treatments.
For the past 10 years, deep brain stimulation (DBS) has been
offered as a treatment for severe and resistant OCD. Nuttin et al.3
were the ﬁrst to demonstrate an improvement in OCD brought
about by DBS of the ventral portion of the anterior limb of the
internal capsule. Other authors have reported similar ﬁndings,
while the French OCD Stimulation study recorded encouraging
results for high-frequency DBS targeting the subthalamic nucleus
(STN).4 This innovative therapeutic approach has yielded extensive
knowledge about the pathophysiology of OCD. For instance, we
now know that brain structures such as the anterior cingulate
cortex,5 orbitofrontal cortex (OFC),6 thalamus and striatum,7 which
are part of the cortico-striato-thalamic loops, are implicated in the
dysfunction that leads to OCD. Neuroimaging has also made a
valuable contribution to our understanding of OCD pathophysiol-
ogy: resting-state or active-state studies using functional magnetic
resonance imaging or positron emission tomography (PET) have
revealed hyperactivation or glucose hypermetabolism of the
anterior cingulate cortex, OFC, caudate nucleus and thalamus in
OCD patients compared with healthy participants.8–10 The two
effective treatments for OCD (CBT and SSRIs) lead to a decrease in
the hypermetabolism observed in the prefrontal cortex (PFC),
especially the OFC (cortico-striato-thalamic circuit).11,12 It turns out
that decreased metabolism in this circuit is also a consequence of
high-frequency DBS. Nuttin et al.3 showed, for instance, that DBS
of the ventral portion of the interior limb of the internal capsule
leads to a decrease in overall brain metabolism and, more
speciﬁcally, in OFC hypermetabolism. Furthermore, one of the
teams in the French OCD Stimulation study4 showed that a
decrease in scores on the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS) was correlated with a decrease in PFC metabolism
during STN stimulation.13 This result strongly suggests that the
efﬁcacy of this technique stems from its capacity to modulate
abnormal activity in circuits involving the OFC, anterior cingulate
cortex and striatum.14 OFC may therefore be a promising
treatment target. Considering this set of important results, which
strongly suggest that the OFC is a neurofunctional marker of OCD
illness, and a potential predictor of response to treatment, we
hypothesized that a noninvasive stimulation technique, such as
repetitive transcranial magnetic stimulation (rTMS), focused on the
OFC might be used as an additional treatment for OCD.
The effect of rTMS on the cortex depends on stimulation
frequency. When the motor cortex is the target, frequencies above
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1 Hz lead to local excitation, whereas frequencies below 1 Hz
trigger inhibition. Stimulation depth seems to depend on the
shape of the coil. A ﬁgure-of-eight coil only allows for very
superﬁcial stimulation (2 cm),15 whereas a double-cone coil results
in deeper stimulation.16
In recent years, the PFC has been the main target in trials of
rTMS in OCD, based on the hypothesis of right PFC hypermeta-
bolism in anxiety disorders and depression.17,18 In accordance
with this hypothesis, several studies have carried out either low-
frequency stimulation of the right PFC or high-frequency
stimulation of the left PFC, with conﬂicting ﬁndings.19–22
In an open-label study,23–25 Mantovani et al.23 reported an
improvement in OCD after rTMS over the pre-SMA and conﬁrmed
these results in a randomized, double-blind study with 18 OCD
patients who received 20 low-frequency rTMS sessions over the
pre-SMA.24 This study was subsequently replicated by Gomes
et al.,26 with 22 patients, with just 10 sessions of low-frequency
rTMS over the pre-SMA. These authors observed a long-lasting
effect of the treatment over 14 weeks.
Owing to the difﬁculty of directly stimulating the OFC, which is
deeply buried beneath the scalp, this structure has been poorly
explored with rTMS. However, in a simple-blind, randomized study
targeting the left OFC with low-frequency stimulation from a
ﬁgure-of-eight coil, Rufﬁni et al.27 observed a clinical improvement
in the active group compared with the sham stimulation group.
In the present pilot study, we set out to assess the efﬁcacy of
low-frequency stimulation of the right OFC in OCD patients using
a double-cone coil. We hypothesized that low-frequency stimula-
tion of the OFC would lead to a reduction in clinical symptoms, as
measured on the Y-BOCS.28,29 We also hypothesized that a
double-cone coil would stimulate the OFC more efﬁciently. As in
previous research using high-frequency DBS, we postulated that
any improvement would be correlated with a reduction in OFC
glucose hypermetabolism.
MATERIALS AND METHODS
Design
This study was conducted in the Adult Psychiatry Department of Rennes
University Hospital, France. The procedure was based on a randomized,
double-blind, crossover design with two 1-week treatment periods (1 week
of active stimulation and 1 week of sham stimulation), separated by a 1-
month washout period.
Eligible patients were randomly assigned in a 1:1 ratio to one of two
groups: one group underwent active stimulation followed by sham
stimulation (on–off group) and the other underwent sham stimulation
followed by active stimulation (off–on group). After the end of each
treatment sequence, the patients underwent a PET scan. The protocol was
approved by the ethics committee of Rennes University Hospital, France
on 1 June 2010 (no. CPP 10/18-760) and by the French regulatory authority
(AFSSAPS; no. 2010-A00294-35). All the patients gave their written
informed consent. Because this preliminary study was essentially experi-
mental, the study was not registered on a public trials database.
Patients
Patients were recruited at the Department of Adult Psychiatry of Rennes
University Hospital. The diagnosis of OCD was made using the MINI.30 The
inclusion criteria for the study were age 18–65 years and a diagnosis of
OCD. In addition, all the patients had to have failed to respond to at least
two different classes of pharmacological treatment (two SSRIs and
clomipramine) used for at least 6 weeks. All patients also had to have
failed to respond to CBT. The exclusion criteria were a diagnosis of another
psychiatric disorder (except for depressive or anxious disorders), a
diagnosis of a signiﬁcant active medical illness, pregnancy, any history of
epilepsy or other neurological illness and any contraindication to TMS or
PET. The patients were not allowed to change their medication during
the trial.
Repetitive transcranial magnetic stimulation
rTMS was performed using a Mag2Health × 100 stimulator (Mag2Health,
Villennes sur Seines, France). We chose a DB-80 butterﬂy double-cone coil
(Mag2Health) to achieve deeper stimulation of the cortex, including the
OFC. For the sham condition, we also used a placebo coil (Medtronic Inc.,
Minneapolis, MN, USA) that reproduced the sounds, clicks and sensations
of actual TMS without the generation of a magnetic ﬁeld. The patients
underwent a visual determination of the motor threshold, deﬁned as the
minimum intensity leading to the most prominent abduction of the left
abductor pollicus brevis muscle after stimulation of the right motor cortex,
holding the coil with the handle pointing backward and laterally at a
45° angle.
The international 10–20 EEG system was used to position the coil over
the right OFC, at the right frontopolar 2 (Fp2) electrode site. Ten sessions
(two per day over 1 week) were administered using the following
parameters: 120% motor threshold, 1 Hz, 1200 pulses per session over the
right OFC.
Randomization and blinding
Randomization was performed without any stratiﬁcation. Patients were
kept blind to the sequence to which they were assigned. Clinical
examination was performed by a psychiatrist who was unaware of the
patients’ stimulation status.
Outcomes
The primary outcome measure for the study was a change in the Y-BOCS
score. Scores on the Clinical Global Impression (CGI)31 scale and the
Montgomery and Asberg Depression Rating Scale (MADRS)32 were used as
secondary outcomes. All the assessments were performed before and after
each sequence, as well as 1 month after the end of the last session. The
side effects of the medical treatment were recorded at each session.
PET scan
A subgroup of patients underwent two PET scans in Rennes, France
(Eugene Marquis Center, Department of Nuclear Medicine) using the same
dedicated Discovery ST PET scanner (GEMS, Milwaukee, WI, USA), with an
axial ﬁeld of view of 15.2 cm.
The patients were studied using 18FDG PET in a resting state. All the
patients were kept on their usual medication. A 144-MBq injection of
18FDG was administered intravenously under standardized conditions (in a
quiet, dimly-lit room with the patient’s eyes and ears open). During the
acquisition, the patient’s head was immobilized using a head-holder. A
cross-laser system was used to achieve stable and reproducible position-
ing. A three-dimensional emission scan was performed 30min post
injection and after X-ray-based attenuation correction. Following scatter,
dead time and random corrections, PET images were reconstructed with
three-dimensional-OSEM, yielding 47 contiguous transaxial 3.75-mm thick
slices.
At the time of acquisition, the neuroisotopist was blind to the
stimulation conditions of each patient. Patients were studied using
18FDG PET in a resting state with their eyes open. They underwent two
scans: one at the end of the active stimulation sequence, the other at the
end of the sham stimulation sequence.
Statistical analysis
We had not calculated beforehand the number of patients we would need
for this pilot study, and we decided to stop inclusions after 3 years. Due to
the basic aspect of the issue being addressed, we only performed per-
protocol analyses. For all results, data are summarized numerically, with
medians (range) for quantitative outcomes (for a small sample size, these
parameters provide the least-biased representation of the data) and
numbers (percentage) for qualitative outcomes. Wilcoxon’s matched-pairs
signed-rank test was used to calculate signiﬁcant differences (two-tailed,
Po0.05) between the active and sham treatments.
The primary outcome was also analyzed by testing three effects:
carryover (physical or psychological effects of the ﬁrst treatment period
still present at the start of the second treatment period), period (difference
in stimulation effects between active–sham group and sham–active group)
and treatment. In this model, the patient factor corresponded to the
random effect (mixed model).
All the statistical analyses were performed with R (R Development
Core Team).
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PET scan analysis
The data were analyzed using statistical parametric mapping software
(SPM2; Wellcome Department of Cognitive Neurology, London, UK) written
in Matlab Version 7 (MathWorks, Sherborn, MA, USA). Statistical parametric
maps are spatially extended statistical processes used to characterize
speciﬁc regional effects in imaging data. They combine the general linear
model (to create the statistical map) with the theory of Gaussian ﬁelds to
make statistical inferences about regional effects.33
All patient images were ﬁrst realigned and spatially normalized to a
standard stereotactic space according to the Talairach-Tournoux atlas.34 An
afﬁne transformation was performed to determine the 12 optimum
parameters for registering the brain to the template. The subtle differences
between the transformed image and the template were then removed by
applying a nonlinear registration method. Finally, the spatially normalized
images were smoothed, using an isotropic 12-mm full-width at half-
maximum Gaussian Kernel to compensate for interindividual anatomical
variability and render the imaging data more normally distributed.
Two contrasts were analyzed:
(1) To determine the direct effects of rTMS, we used the ‘population main
effect, 2 cond’s, 1scan/cond (paired t test)’ condition. Clusters of at
least 31 contiguous voxels, with a two-tailed P-value threshold of 0.005
(corrected for multiple comparisons at cluster level), were considered
to be signiﬁcantly different (as expected and deﬁned by SPM analyses).
(2) To validate our a priori hypothesis that the beneﬁts of rTMS are related
to a decrease in OFC metabolism, we used a general linear
‘multisubject conditions and covariates’ model, testing it at each
voxel, with the Y-BOCS score as a covariate. This yielded a regression
coefﬁcient that was then transformed into a t-value. We studied the
results for the OFC using the SPM Anatomy toolbox.35 We then
calculated t statistics SPMs, thresholded at P= 0.005, corrected for
multiple comparisons at cluster level, voxel number per cluster k428
(as expected and deﬁned by SPM analyses).
All MNI coordinates were transformed by applying procedures devel-
oped by Matthew Brett (http://www.mrc-cbu.cam.ac.uk/Imaging) and
reported here, based on the Talairach atlas.
RESULTS
Recruitment and baseline data
Supplementary Figure 1 presents the study’s ﬂowchart. Between
March 2009 and March 2012, a total of 22 patients with moderate-
to-severe OCD were recruited. Two patients were included despite
an additional diagnosis of psychotic disorder and one despite a
diagnosis of anorexia. All three inclusions were deemed to be
major deviations from the protocol, and these patients were
excluded from all per-protocol analyses. The 19 remaining patients
who had begun the trial completed both sequences in a double-
blind, crossover and randomized fashion, in accordance with the
study protocol. Two patients were lost to follow-up at the ﬁnal
assessment. Medication was held constant throughout the
2 months of the protocol.
At the time of their inclusion in the study, six patients met the
criteria for current major depressive disorder. Table 1 provides the
baseline data for the 19 patients at inclusion. At the beginning of
the study, pharmacological treatment included SSRIs (12/19),
antipsychotics (7/19), tricyclic antidepressants (10/19), benzodia-
zepines (5/19).
Primary outcome
At day 7, we observed a signiﬁcant decrease in Y-BOCS scores,
compared with baseline, after both active (Po0.01) and sham
(P= 0.02) stimulation. This decrease tended to be greater after
active stimulation than after sham stimulation: − 6 (–29, 0) points
versus − 2 (−20, 4) points (P= 0.07).
At day 35, no difference was observed in this decrease from the
Y-BOCS baseline between active stimulation and sham stimula-
tion: − 1 (−15, 5) points versus 0 (−14, 6) points (P= 0.94).
We did not detect a signiﬁcant effect of either carryover or
period on these Y-BOCS differences, indicating that the effects of
the ﬁrst treatment period did not persist beyond the washout
period.
Figure 1 indicates the changes in OCD severity observed in the
19 patients during the crossover study (summary measures and
individual data).
Secondary outcomes
Table 2 sets out the results for all the secondary outcomes. No
speciﬁc change was observed in MADRS scores.
PET scan data
Ten patients took part in the PET substudy. Areas of signiﬁcant
difference found by comparing the patients in the active and
sham conditions are shown in Figure 2a.
In the active stimulation condition, there were a signiﬁcant
decrease in metabolism in the right frontal lobe (superior gyrus
(Brodmann area, BA 9), middle gyrus (BA 10), orbital gyrus (BAs 47
and 11)), left anterior cingulate gyrus (BA 25) left frontal lobe
(orbital gyrus (BA 11)) and left putamen (Table 3). These results
revealed a decrease in the metabolism of the bilateral orbito-
frontal lobes, with a more extensive decrease in the right side.
No increase in brain metabolism was found in the active
stimulation condition (no cluster signiﬁcant at Po0.005 corrected
on cluster level).
When we investigated the neural correlates of the clinical
improvement by correlating the decrease in the Y-BOCS score and
changes in the PET signal between the two sessions (on versus off,
Figure 2b), we found that the decrease in the Y-BOCS score was
correlated with a decrease in the metabolic activity of the right
OFC (Talairach coordinates +56 +26 − 16, BA 47).
Table 1. Baseline data for the 19 patients at inclusion
All patients On–off
group
Off–on
group
Age 39 (24, 56) 40 (24, 56) 39 (26, 56)
Sex (women) 15 (79%) 8 (80%) 7 (78%)
Age at onset 18 (7, 48) 18 (14, 32) 15 (7, 48)
Y-BOCS 32 (15, 36) 32 (16, 36) 32 (15, 36)
Y-BOCS obsession
subscale
16 (8, 18) 16 (8, 18) 16 (11, 18)
Y-BOCS compulsion
subscale
16 (0, 20) 17 (0, 20) 16 (1, 19)
CGI 6 (5, 7)
(NA= 6)
7 (5, 7)
(NA= 4)
6 (5, 7)
(NA= 2)
MADRS 12 (3, 35)
(NA= 3)
22 (3, 35)
(NA= 1)
10 (6, 16)
(NA= 2)
Current medication (NA= 2) (NA= 2)
SRI 12 (70%) 5 (63%) 7 (78%)
SNRI 1 (6%) 1 (13%) 0 (0%)
Tricyclic antidepressant 10 (60%) 6 (75%) 4 (44%)
Antipsychotics 7 (41%) 1 (13%) 6 (67%)
Mood stabilizer 2 (11%) 1 (13%) 1 (11%)
Antihistamine 1 (6%) 0 (0%) 1 (11%)
Benzodiazepine 5 (26%) 3 (38%) 2 (22%)
Abbreviations: CGI, Clinical Global Impression Scale; MADRS, Montgomery
and Asberg Depression Rating Scale; NA, number of missing data; SNRI,
serotonin and norepinephrine reuptake inhibitors; SRI, serotonin reuptake
inhibitors; Y-BOCS, Yale-Brown Obsessive Compulsive Scale. For all results,
data are summarized numerically, with medians (range) for quantitative
outcomes and numbers (percentage) for qualitative outcomes.
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Treatment safety
No serious adverse event was observed during the study. Three
patients complained of headache, which resolved without any
speciﬁc treatment.
DISCUSSION
Summary of evidence
Our study revealed a trend toward statistical signiﬁcance
concerning the efﬁcacy of rTMS over the right OFC in OCD at
day 7, but no difference was observed a month after the end of
the second treatment period. These results are in line with
previous ﬁndings27 showing that low-frequency rTMS over the left
OFC produces signiﬁcant, but time-limited, improvements in OCD
patients compared with sham treatment. However, by synchroniz-
ing these clinical ﬁndings with data yielded by PET scans, we were
able to investigate them from a remarkable new perspective. The
PET substudy showed that the use of rTMS over the right OFC is
associated with a bilateral decrease in the glucose metabolism of
that structure. Although different effects of active and sham rTMS
on brain metabolism do not strictly exclude the possibility of a
placebo effect, it should be noted that the metabolic changes
occurred predominantly in front of the coil (BAs 11, 47 and BA 10),
and in the right side rather than the left (only BA 11), and a causal
relationship therefore seems the more plausible hypothesis. This
result suggests that the modulation of the right OFC with rTMS
mirrors the metabolic modiﬁcations observed with STN DBS in
parallel with an improvement in OCD symptomatology (Le Jeune
et al.13). The correlation between the decrease in metabolism and
the improvement in OCD could be interpreted as a causal
relationship between the treatment, the decrease in OFC
metabolism and the therapeutic response. We have previously
indicated that the OFC’s glucose hyperactivity could represent a
therapeutic neurofunctional marker of the disease, with a
relationship between a decrease in its activity and the efﬁcacy
of high-frequency STN DBS.13
Taken together, these results support the hypothesis of a
dysfunction of the orbital-subcortical loop in OCD, with two
potential basal ganglia targets for brain stimulation techniques
(STN or striatum) in resistant and very severe OCD patients, and
rTMS over the prefrontal cortex, in particular the OFC, supple-
menting the classic SSRI and CBT approaches.
Concerning rTMS efﬁcacy, our results underline the theoretical
value of stimulating the OFC in OCD, and suggest that a double-
cone coil is capable of stimulating this deeply buried structure.
Our study is the ﬁrst to have used such a coil to target the OFC. We
can surmise that focusing more accurately on the desired target
and using a more appropriate coil would result in a stronger
effect. Nevertheless, the positive trend observed in the OCD
symptomatology at day 7 was no longer present 1 month later.
This time-limited improvement, previously encountered after 10
sessions of 1-Hz rTMS over the OFC27 has a very practical
implication, for as there is no sustained beneﬁt over time, the
usefulness of OFC rTMS in day-to-day clinical practice is therefore
limited, given actual stimulation parameters. Nonetheless, rTMS
seems a promising tool for exploring the impact of OFC
neuromodulation in OCD, as this structure’s hyperactivity is
strongly implicated in OCD physiopathology. The scientiﬁc interest
therefore seems greater than the clinical interest, and justiﬁes the
use of the per-protocol analysis in the present study, which was
designed to determine the biological effect of rTMS in ‘pure’ OCD
patients.
Limitations
The present study suffered from low power, which is an endemic
problem in the ﬁeld of neuroscience.36 Nevertheless, despite the
lack of power in this preliminary study, the trend we observed
concerning clinical efﬁcacy was in line with previous research
results,27 suggesting that OFC rTMS in OCD is a potential
treatment that now needs conﬁrmation in an extended study
with a larger sample of patients.
Second, there were substantial (and statistically signiﬁcant)
responses in the sham condition group. This may have been, in
part, due to the extra attention the OCD patients were given, in
line with previous ﬁndings (Mansur et al., 2011).37
Third, the crossover procedure in this study could be regarded
as questionable. Even though our objective was to reproduce the
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Figure 1. Changes in OCD severity in 19 patients during the
crossover study. Data are shown at the time of inclusion in the study
(month 0), after the ﬁrst period of active or sham stimulation (day 7),
before (month 1) and after (day 7) the second period of active or
sham stimulation and at the end of the study (month 2). (a) Shows
the mean (s.d.) scores on the Yale-Brown Obsessive Compulsive
Scale (Y-BOCS) for the active–sham group (lines) and sham–active
group (dashed lines). (b) Shows the individual Y-BOCS scores for the
active–sham and sham–active groups. The active stimulation period
is shown in red and the sham stimulation period in orange. OCD,
obsessive-compulsive disorder.
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principle of a similar study conducted within the ﬁeld of OCD,4 the
duration of the rTMS sequence we administered to OCD patients,
as well as the 1-month washout period could be criticized.
Moreover, this type of design is prone to unblinding, in that small
differences between the sham and active coils may be noticed by
the patients, and therefore interfere with their expectations of
treatment efﬁcacy, resulting in differential placebo effects across
groups. Statistical modeling allowed us to ascertain that there was
no signiﬁcant effect either of carryover or of period on Y-BOCS
differences. Nevertheless, these models can suffer from low
power, and a closer inspection of Figure 2 suggests that the
treatment (be it active or sham) had a greater effect when it was
administered in the ﬁrst period. This argues against the presence
of unblinding, as we would have expected a greater improvement
for active stimulation after the second session (compared with the
ﬁrst one), when patients had previously experienced sham
stimulation and could therefore guess that they were receiving
the active treatment. In addition, this aspect of the ﬁgure might be
in favor of a remanent effect of the last pharmacological change.
We acknowledge that the 6-week washout period was quite short,
and 12 weeks would have been preferable. Even though the
randomized procedure can compensate for this possible con-
founding factor, it may have resulted in greater variability and
thus in a further loss of statistical power.
Table 2. Changes in OCD severity, clinical impressions and depression
Active period Sham period P-value
Change after treatment (day 7)
Y-BOCS − 6 (−29, 0) − 2 (−20, 4) 0.07
Y-BOCS obsession subscale − 2 (0, 16) − 1 (−2, 10) 0.08
Y-BOCS compulsion subscale − 3 (0, 13) − 1 (−3, 10) 0.22
CGI 3 (1, 4) (NA= 3) 3 (1, 5) (NA= 1) 0.35
MADRS (change) − 2 (−28, 2) (NA= 2) 0 (−19, 7) (NA= 5) 0.64
Change at follow-up (day 35: 1 month after treatment)
Y-BOCS − 1 (−15, 5) 0 (−14, 6) (NA= 2) 0.94
Y-BOCS obsession subscale 0 (−2, 7) 0 (−5, 8) (NA= 2) 0.75
Y-BOCS compulsion subscale 0 (−3, 8) 0 (−1, 6) (NA= 2) 0.59
CGI 3 (1, 4) (NA= 1) 3 (1, 5) (NA= 5) 0.74
MADRS 0 (−21, 10) (NA= 3) − 1 (−6, 13) (NA= 6) 0.69
Abbreviations: CGI, Clinical Global Impression Scale; MADRS, Montgomery and Asberg Depression Rating Scale; NA, number of missing data; OCD, obsessive-
compulsive disorder; Y-BOCS, Yale-Brown Obsessive Compulsive Scale. For all results, data are summarized numerically, with medians (range) for quantitative
outcomes and numbers (percentage) for qualitative outcomes.
Figure 2. (a) Statistical parametric map showing decreased cerebral
glucose metabolism in 10 OCD patients treated with rTMS,
comparing active stimulation versus sham stimulation conditions.
Areas with signiﬁcant decreases (Po0.005, adjusted for multiple
comparisons at cluster level) are shown on three telescoped
orthogonal views. (b) Correlation between metabolic changes
induced by rTMS and concomitant clinical improvement (Y-BOCS
scores). Whole-brain analysis shows a signiﬁcant cluster of correla-
tion in the orbitofrontal cortex (Brodmann area 47) with the
decrease in the Y-BOCS score.
Table 3. Regions with decreased glucose metabolism after active
rTMS stimulation in 10 OCD patients (Po0.005, multiple comparison
corrected on cluster level, voxel number per cluster k431)
Region Talairach
coordinates
Z-value Voxel
number
X Y Z
Right frontal lobe, middle
gyrus, BA 9
30 34 32 4.50 424
Right frontal lobe, middle
gyrus, BA 10
24 52 20 4.24 303
Left putamen − 22 − 6 10 4.05 110
Right frontal lobe, middle
gyrus, BA 10
20 52 − 10 3.39 86
Left cingulate gyrus, BA 25 − 2 10 − 2 3.38 105
Right orbital gyrus, BA 47 18 32 − 24 3.30 94
Right orbital gyrus, BA 11 12 32 − 30 3.14 94
Left orbital (rectal) gyrus, BA
11
− 10 22 −22 3.22 98
Abbreviations: BA, Brodmann area; OCD, obsessive-compulsive disorder;
rTMS, repetitive transcranial magnetic stimulation. The results are classiﬁed
according to z-score values.
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Moreover, in OCD, a high anxiety state increases obsessive and
compulsive symptoms. Treatment onset per se may represent a
factor for anxiety, particularly in the ﬁrst period. We did not
speciﬁcally assess this dimension. However, the randomized order
of treatment period lessened the consequences of this lack
of data.
Prospects
On the basis of the parameters we used in our study, our results
hold out three main prospects. First of all, this tool could be used
in basic research to explore the central role of the OFC in OCD10,38
and its functional interconnections with other structures, such as
the striatum. These links between neuroanatomical structures
could be related to the serotonin dysfunction that is the chief
suspect in the pathophysiology of OCD.39,40 The speciﬁc
abnormality of these regions, as well as the ways in which they
interact to produce obsessions and compulsions, are as yet
unknown. Animal models have recently yielded fresh information
about these interconnections, showing that OFC lesions in rats
increase compulsive behavior, and that this increase can be
prevented by the systemic administration of the SSRI paroxetine.
Animal study results also shed new light on the role of a
dysfunctional striatal serotonergic system.41 In humans, rTMS will
allow researchers to explore these issues because it is a
noninvasive tool.
A second and equally important point concerns the therapeutic
applications arising from our current ﬁndings. The parameters for
stable improvement now need to be identiﬁed, and a neurona-
vigation system focusing on the OFC, especially the lateral side,
might well prove helpful in that respect, as might an increase in
the number of stimulation sequences. Furthermore, the use of a
more appropriate coil to reach deeper below the scalp would
certainly increase the potential efﬁcacy of the technique.
The third issue relates to the generalization of our ﬁnding at the
individual level, that is, the ability to decipher the prognostic value
of this therapeutic approach for a given patient. In this regard, it
would be well worth conducting a diagnostic accuracy study of
OFC hyperactivity.
To conﬁrm these promising ﬁndings and to address the above
mentioned limitations, we are planning to conduct a randomised,
single-blind, controlled trial of active OFC rTMS versus sham OFC
rTMS with a blinded outcome assessment. Based on this study, we
predict an effect size of nearly 0.5. The statistical analysis
performed on the main endpoint will be conducted using a
two-sided test with a Type I error of 5%. Based on these
hypotheses, the sample size, computed to guarantee a power of
80%, will have to be 60 patients per group (that is, a total of 120
patients).
CONCLUSION
The results of this preliminary study suggest that the OFC is a
possible neuroanatomical target for OCD treatment, especially
rTMS. Over the past 20 years, brain stimulation techniques have
shown themselves to be genuine alternatives to classic treatments
such as CBT and SSRIs. If conﬁrmed, they may prove at least as
effective as SSRIs, and reﬂect a rational approach to the disease
based on the hypothesis of a dysfunctional PFC-basal ganglia
circuit. Moreover, the results of this study allow us to regard the
OFC as an additional neuroanatomical target, and one that is
easier to reach than the striatum or the STN favored in
neurosurgical approaches. Larger trials using rTMS over the OFC
should be carried out to conﬁrm our results and to conﬁrm rTMS
as an effective and complementary treatment for OCD.
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